发明授权
- 专利标题： Pharmaceutical formulations containing an SGLT2 inhibitor
- 专利标题（中）： 含有SGLT2抑制剂的药物制剂
-
申请号： US12949473申请日： 2010-11-18
-
公开(公告)号： US08221786B2公开(公告)日： 2012-07-17
- 发明人: Dilbir S. Bindra , Mandar V. Dali , Prakash V. Parab , Jatin M. Patel , Li Tao , Ravindra W. Tejwani , Nipa Vatsaraj , Yongmei Wu
- 申请人： Dilbir S. Bindra , Mandar V. Dali , Prakash V. Parab , Jatin M. Patel , Li Tao , Ravindra W. Tejwani , Nipa Vatsaraj , Yongmei Wu
- 申请人地址： US NJ Princeton
- 专利权人： Bristol-Myers Squibb Company
- 当前专利权人： Bristol-Myers Squibb Company
- 当前专利权人地址： US NJ Princeton
- 代理机构： McDonnell Boehnen Hulbert & Berghoff LLP
- 主分类号： A61K9/48
- IPC分类号： A61K9/48 ; A61K31/70 ; A61K9/30 ; A61P3/00 ; A61P9/00
摘要：
Pharmaceutical formulations are provided which are in the form of capsules or tablets for oral use and which include a medicament dapagliflozin or its propylene glycol hydrate and a pharmaceutical acceptable carrier therefor, which formulation is designed for immediate release.
公开/授权文献
信息查询
